Translational Laboratory Shared Service

转化实验室共享服务

• 批准号: 9750151
• 负责人: Rena Lapidus
• 金额: $ 6.65万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9750151
• 关键词: Animal Experiments; Animals; Apoptosis; Applications Grants; Baltimore; Biological; Biological Assay; Biometry; Bone Marrow; Cancer Center; Cancer Center Support Grant; Cell Line; Cell Proliferation; Cells; Cigarette; Clinical; Clinical Data; Clinical Research; Clinical Trials; Clinical trial protocol document; Communication; Consultations; Correlative Study; County; Custom; DNA; Data; Doctor of Philosophy; Drug Kinetics; Evaluation; Flow Cytometry; Funding; Genomics; Grant; Hematologic Neoplasms; Hormone Responsive; Human; Image; In Vitro; Institutes; Investigational Therapies; Journals; Laboratories; Legal patent; Letters; Malignant Neoplasms; Maryland; Medical; Medical center; Methodology; Mission; Modeling; Molecular Biology; Nature; Pathology; Peer Review; Peripheral Blood Mononuclear Cell; Pharmacodynamics; Pharmacy Schools; Phase; Physicians; Plasma; Population Sciences; Pre-Clinical Model; Protocols documentation; Public Health Schools; Publications; RNA; Research; Research Personnel; Research Support; Resources; School Dentistry; Services; Solid Neoplasm; Source; Specimen; Specimen Handling; Students; System; Therapeutic; Translating; Translational Research; Universities; acronyms; anticancer research; base; biobank; cancer therapy; college; cytotoxicity; education resources; in vitro Assay; in vivo; investigator-initiated trial; medical schools; member; neoplasm immunotherapy; novel; novel anticancer drug; off-patent; pre-clinical; programs; structural biology; training opportunity; translational impact; tumor; tumor immunology; virology

7.0 Abstract: Translational Laboratory Shared Service The Translational Laboratory Shared Service (TLSS) at UMGCC generates preclinical (cell- and animal-based) and clinical data for investigators to support cutting-edge research and provides preliminary data for grant submissions and letters of intent for Phase I/II clinical trials, which is a major thrust of TLSS activity. The TLSS also develops in vitro and in vivo preclinical models for evaluation of novel anticancer agents to translate scientific ideas into therapeutics. The TLSS supports many Phase I/II clinical trials at UMGCC by isolating biological specimens and developing and executing assays for correlative studies to support these trials. The TLSS is unique in that it provides a combination of services and resources usually not offered by any one core, predominantly supporting physicians engaged in clinical and translational research and preclinical investigators, fellows, and students conducting preclinical in vivo studies. The TLSS supports Phase I/II clinical trials, provides access to in vivo tumor models, generates preliminary data for grant applications, supports submission of patent applications, and generates data that provide the basis for new clinical trial protocols. These efforts have resulted in publications that include TLSS staff as coauthors, clearly demonstrating the positive impact the TLSS has on cancer research at UMGCC. Since 2010, the TLSS has provided support for 27 clinical trials, including providing preliminary data for 4 new investigator-initiated trials; carried out over 200 animal experiments through an umbrella animal protocol that streamlines investigators’ access to animal studies; and provided preliminary data to 8 peer-reviewed, funded grant applications. In 2014, the TLSS supported 46 Cancer Center members spanning all 5 research programs (18 percent of all UMGCC members), 63 percent of whom have peer-reviewed funding. The TLSS supports many cancer-related publications annually, many in high-impact journals including Nature Communications and Clinical Cancer Research.

7.0翻译后摘要：实验室共享服务 UMCCC的转化实验室共享服务（TLSS）生成临床前（基于细胞和动物） 研究人员的临床数据，以支持尖端研究，并提供初步数据的赠款 I/II期临床试验的提交和意向书，这是TLSS活动的主要推动力。TLSS 还开发了体外和体内临床前模型，用于评估新型抗癌药物， 将科学理念转化为治疗学TLSS支持UMCCC的许多I/II期临床试验， 生物样本，并开发和执行相关研究的测定，以支持这些试验。的 TLSS的独特之处在于它提供了通常不由任何一个核心提供的服务和资源的组合， 主要支持从事临床和转化研究以及临床前 进行临床前体内研究的研究人员、研究员和学生。 TLSS支持I/II期临床试验，提供体内肿瘤模型，生成初步的 专利申请数据，支持专利申请的提交，并生成提供 新的临床试验方案的基础。这些努力的结果是出版了包括TLSS工作人员在内的出版物， 共同作者，清楚地证明了TLSS对UMCCC癌症研究的积极影响。以来 2010年，TLSS为27项临床试验提供了支持，包括为4项新的 实验室发起的试验;通过一项保护性动物方案进行了200多项动物实验， 简化了研究人员对动物研究的访问;并向8个同行评审，资助 补助金申请。 2014年，TLSS支持了46名癌症中心成员，涵盖所有5个研究项目（占所有研究项目的18 UMCCC成员），其中63%的人有同行评审的资金。TLSS支持许多与癌症相关的 每年出版，许多在高影响力的期刊，包括自然通讯和临床癌症 Research.